收费全文 | 7125篇 |
免费 | 448篇 |
国内免费 | 29篇 |
耳鼻咽喉 | 80篇 |
儿科学 | 119篇 |
妇产科学 | 81篇 |
基础医学 | 889篇 |
口腔科学 | 263篇 |
临床医学 | 457篇 |
内科学 | 1746篇 |
皮肤病学 | 214篇 |
神经病学 | 496篇 |
特种医学 | 609篇 |
外科学 | 1007篇 |
综合类 | 54篇 |
预防医学 | 257篇 |
眼科学 | 312篇 |
药学 | 451篇 |
中国医学 | 26篇 |
肿瘤学 | 541篇 |
2023年 | 34篇 |
2021年 | 99篇 |
2020年 | 71篇 |
2019年 | 89篇 |
2018年 | 125篇 |
2017年 | 103篇 |
2016年 | 140篇 |
2015年 | 155篇 |
2014年 | 167篇 |
2013年 | 205篇 |
2012年 | 291篇 |
2011年 | 301篇 |
2010年 | 204篇 |
2009年 | 165篇 |
2008年 | 286篇 |
2007年 | 341篇 |
2006年 | 318篇 |
2005年 | 350篇 |
2004年 | 275篇 |
2003年 | 314篇 |
2002年 | 325篇 |
2001年 | 328篇 |
2000年 | 314篇 |
1999年 | 256篇 |
1998年 | 80篇 |
1997年 | 71篇 |
1996年 | 47篇 |
1995年 | 48篇 |
1994年 | 56篇 |
1993年 | 43篇 |
1992年 | 192篇 |
1991年 | 161篇 |
1990年 | 143篇 |
1989年 | 154篇 |
1988年 | 131篇 |
1987年 | 146篇 |
1986年 | 141篇 |
1985年 | 144篇 |
1984年 | 100篇 |
1983年 | 72篇 |
1982年 | 40篇 |
1979年 | 65篇 |
1978年 | 39篇 |
1977年 | 35篇 |
1976年 | 34篇 |
1975年 | 43篇 |
1973年 | 33篇 |
1971年 | 39篇 |
1970年 | 37篇 |
1969年 | 40篇 |
Background
Anticoagulation therapy, particularly subcutaneous heparin therapy, is recommended for cancer-associated thrombosis. However, not starting or discontinuing anticoagulation was not rare. The aim of the present study was to examine the practical issues related to anticoagulation therapy and effects of subcutaneous heparin therapy for cancer-associated stroke.Methods
Patients with cancer-associated stroke in our stroke center between October 2014 and August 2017 who were diagnosed as having acute ischemic stroke based on diffusion-weighted imaging were retrospectively enrolled. Baseline clinical characteristics, heparin injection, reasons for no subcutaneous heparin therapy, and clinical outcomes were collected.Results
A total of 59 patients with cancer-associated stroke (75 ± 10 years old, male 42%) were enrolled. Lung cancer was the most frequently observed cancer (n = 17, 29%), followed by gastric cancer (n = 8, 14%) and pancreatic cancer (n = 8, 14%). Of the 19 patients (32%) who underwent subcutaneous heparin therapy, it was discontinued in 9 (47%), mainly because of patients’ medical conditions (deterioration of cancer or hemorrhagic complication). Ten patients with long-term subcutaneous heparin therapy did not have stroke recurrence. In contrast, among nine patients who discontinued subcutaneous heparin therapy, three (33%) had recurrence of ischemic stroke. Of the 40 patients without subcutaneous heparin therapy, the main reasons for no subcutaneous heparin therapy were the patients’ medical conditions (n = 22, 55%).Conclusions
Although subcutaneous heparin therapy was given to only one third of cancer-associated stroke patients, long-term subcutaneous heparin therapy might prevent recurrence of cancer-associated stroke. 相似文献Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, its effectiveness and safety in patients with poor performance status (PS) are unknown.
MethodsEnrolled patients showed disease progression after treatment with gefitinib, erlotinib, or afatinib; T790M mutation; stage IIIB, IV, or recurrent disease; and PS of 2–4. Osimertinib was orally administered at a dose of 80 mg/day. The primary endpoint of this phase II study (registration, jRCTs061180018) was response rate and the secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate, and safety.
ResultsThirty-three patients were enrolled, of which 69.7% and 24.2% had PS of 2 and 3, respectively. One patient was excluded due to protocol violation; in the remaining 32 patients, the response rate was 53.1%; disease control rate was 75.0%; PFS was 5.1 months; and OS was 10.0 months. The most frequent adverse event of grade 3 or higher severity was lymphopenia (12.1%). Interstitial lung disease (ILD) was observed at all grades and at grades 3–5 in 15.2% (5/33) and 6.1% (2/33) of patients, respectively. Treatment-related death due to ILD occurred in one patient. Patients negative for activating EGFR mutations after osimertinib administration had longer median PFS than those positive for these mutations.
ConclusionOsimertinib was sufficiently effective in EGFR-TKI-resistant, poor PS patients with T790M mutation-positive advanced NSCLC. Plasma EGFR mutation clearance after TKI treatment could predict the response to EGFR-TKIs.
相似文献